Vemurafenib + Sorafenib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas Cancer
Conditions
Pancreas Cancer
Trial Timeline
Oct 28, 2021 → Dec 30, 2024
NCT ID
NCT05068752About Vemurafenib + Sorafenib
Vemurafenib + Sorafenib is a phase 2 stage product being developed by Bayer for Pancreas Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05068752. Target conditions include Pancreas Cancer.
What happened to similar drugs?
1 of 5 similar drugs in Pancreas Cancer were approved
Approved (1) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05068752 | Phase 2 | Active |
Competing Products
20 competing products in Pancreas Cancer